RxDoctor Payments DataLook up a doctor →

Ammon Larsen, MD

Dermatology · Loveland, CONPI 1982044012

Payments from drug & device makers

$620,183in general payments, 2019–2025

Across 1,387 payments — averaging $447.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$170K
  • Lilly USA, LLC$142K
  • UCB, Inc.$98K
  • Galderma Laboratories, L.p.$80K
  • Sanofi$59K
  • Regeneron Healthcare Solutions, Inc.$31K
  • plus $40K from 26 others

What the payments were for

  • Consulting fees$35,2156%
  • Speaking & faculty fees$521,22484%
  • Travel & lodging$37,5706%
  • Food & beverage$25,7174%
  • Education$4560%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$620,183 in reported general payments places this provider in the 95th percentile of 280 dermatology providers in Colorado.

See all dermatology providers in Colorado

Medicare billing

Part B allowed, 2024
$315,200
Medicare patients
865
Services billed
4,844

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab108$424,497
Cosentyx Unoready PenSecukinumab29$322,823
Skyrizi PenRisankizumab-Rzaa14$307,018
RinvoqUpadacitinib39$255,671
OdomzoSonidegib Phosphate19$244,282
Humira(Cf) PenAdalimumab12$164,394
NemluvioNemolizumab-Ilto14$109,416
OpzeluraRuxolitinib Phosphate11$22,439
Clobetasol Propionate214$9,382
Tacrolimus19$3,941
Ketoconazole108$3,131
Ivermectin22$2,148
Triamcinolone Acetonide148$2,043
Tretinoin18$2,029
Metronidazole22$1,162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$169,692$255,67139 claims
Galderma Laboratories, L.p.Nemluvio$80,244$109,41614 claims
Incyte CorporationOpzelura$2,447$22,43911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 280 dermatology providers in Colorado.

Other dermatology in Loveland

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →